Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O. Callon S, et al. Among authors: perrier m. Ther Adv Med Oncol. 2023 Jan 10;15:17588359221148536. doi: 10.1177/17588359221148536. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36643657 Free PMC article.
Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN).
Brugel M, Marulier T, Evrard C, Carlier C, Tougeron D, Piessen G, Truant S, Turpin A, Williet N, Botsen D, Brasseur M, Perrier M, Bouché O. Brugel M, et al. Among authors: perrier m. Pancreatology. 2023 Sep;23(6):622-629. doi: 10.1016/j.pan.2023.06.010. Epub 2023 Jun 19. Pancreatology. 2023. PMID: 37394294
Prevalence of cannabidiol (CBD) consumption and cancer patients' expectations in one oncology day-hospital: A cross-sectional study and questionnaire validation.
Le Bozec A, Guédon M, Brugel M, Laurent M, Carlier C, Hettler D, Perrier M, Aubert L, Slimano F, Mongaret C, Bouché O. Le Bozec A, et al. Among authors: perrier m. J Oncol Pharm Pract. 2023 Jul 12:10781552231187136. doi: 10.1177/10781552231187136. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37437182
Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC).
Brugel M, Callon S, Carlier C, Amroun KL, Botsen D, Kianmanesh R, Perrier M, Piardi T, Renard Y, Rhaiem R, El Balkhi S, Bouché O. Brugel M, et al. Among authors: perrier m. United European Gastroenterol J. 2024 Sep;12(7):951-959. doi: 10.1002/ueg2.12602. Epub 2024 Aug 8. United European Gastroenterol J. 2024. PMID: 39118264 Free PMC article.
Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists.
Gossery C, Clarenne J, Barraud S, Brugel M, Boulin M, Carlier C, Perrier M, Botsen D, Hettler D, Kanagaratnam L, Mongaret C, Bouché O, Slimano F. Gossery C, et al. Among authors: perrier m. Support Care Cancer. 2024 Nov 14;32(12):791. doi: 10.1007/s00520-024-09014-z. Support Care Cancer. 2024. PMID: 39542931
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: perrier m. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
240 results